Innovation

Cell & Gene Therapy

Taranis Capital and EEC Partner to Build Next-Generation Data Centres

Taranis Capital and Emaar Executive Company partner to develop carrier-neutral data centres across Saudi Arabia, supporting rising AI and cloud demand under Vision 2030

Taranis Capital Limited (“Taranis”), a DFSA-regulated investment firm based in Dubai International Financial Centre (DIFC), has signed a Memorandum of Understanding (MOU) with Emaar Executive Company (EEC) to develop, construct, and operate a portfolio of next-generation, carr

Mark Walker  · 
AgriTech

UAE's agritech push: food security as industrial policy

The Emirates Food Security Council has expanded its mandate to cover controlled-environment agriculture, cell-cultured protein, and desalination-linked aquaculture — with state capital behind each.

The UAE imports roughly 85 per cent of its food. For a country that has made state-capacity industrial policy a signature of its modernisation, that number is not a fact to be accepted — it is a problem to be solved with capital and technology.

The Biotech Times Editorial Team  · 
Biologics
Cell & Gene Therapy

NurExone advances ExoPTEN optic nerve programme to rabbit study

Positive rat-model data showing statistically significant retinal recovery will support a planned larger-animal study for NurExone's exosome candidate ExoPTEN.
Positive rat-model data showing statistically significant retinal recovery will support a planned larger-animal study for NurExone's exosome candidate ExoPTEN.
The Biotech Times Editorial Team  · 
Digital Health

EliseAI partners with Nextech to embed voice AI in specialty clinics

EliseAI and Nextech are co-developing deeper API integrations to bring agentic voice AI to ophthalmology, dermatology, and orthopaedic practices.
EliseAI and Nextech are co-developing deeper API integrations to bring agentic voice AI to ophthalmology, dermatology, and orthopaedic practices.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

InnoCare wins China IND approval for TL1A/IL-23p19 bispecific ICP-B161

InnoCare Pharma has received NMPA clearance to trial ICP-B161, a long-acting bispecific antibody targeting two key IBD pathways, in China.
InnoCare Pharma has received NMPA clearance to trial ICP-B161, a long-acting bispecific antibody targeting two key IBD pathways, in China.
The Biotech Times Editorial Team  · 
Medical Devices
Pharmaceuticals

Beyond Air posts record $2.3m quarter as LungFit PH adoption grows

Beyond Air said Q3 2026 revenue rose 30% sequentially to $2.3m, its highest ever, while its second-generation nitric oxide system awaits FDA approval.
Beyond Air said Q3 2026 revenue rose 30% sequentially to $2.3m, its highest ever, while its second-generation nitric oxide system awaits FDA approval.
The Biotech Times Editorial Team  · 
Medical Devices

Stryker names Spencer Stiles CEO as Kevin Lobo moves to Executive Chair

Stryker's 27-year veteran Spencer Stiles will become CEO on 1 January 2027, as Kevin Lobo transitions to Executive Chair after tripling annual revenues.
Stryker's 27-year veteran Spencer Stiles will become CEO on 1 January 2027, as Kevin Lobo transitions to Executive Chair after tripling annual revenues.
The Biotech Times Editorial Team  · 
Synthetic Biology
AgriTech

Fieldstone Bio joins Rio Tinto mining accelerator

The synthetic biology startup will work with Rio Tinto's geologists to commercialise biosensor-based critical-mineral measurement for exploration teams.
The synthetic biology startup will work with Rio Tinto's geologists to commercialise biosensor-based critical-mineral measurement for exploration teams.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Teva wins FDA approval for WELTRUZA once-monthly olanzapine

Teva's subcutaneous olanzapine LAI requires no loading doses, no oral supplementation and no post-injection monitoring, the FDA ruled.
Teva's subcutaneous olanzapine LAI requires no loading doses, no oral supplementation and no post-injection monitoring, the FDA ruled.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics

NeuroOne joins Dartmouth NIH grant for neurotransmitter sensing

NeuroOne will receive around $200,000 from a $1 million NIH BRAIN Initiative grant to co-develop real-time neurotransmitter sensing with Dartmouth College.
NeuroOne will receive around $200,000 from a $1 million NIH BRAIN Initiative grant to co-develop real-time neurotransmitter sensing with Dartmouth College.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics
Digital Health

Spectral AI files NTAP application for DeepView burn-wound system

Spectral AI has applied to CMS for additional Medicare reimbursement for its AI-powered DeepView burn-wound imaging device, cleared by the FDA in May
Spectral AI has applied to CMS for additional Medicare reimbursement for its AI-powered DeepView burn-wound imaging device, cleared by the FDA in May
The Biotech Times Editorial Team  · 
Medical Devices
Biologics

Vascudyne lab-grown bypass vessel sustains flow at two-year mark

The Minnesota biotech presented two-year clinical patency data for its acellular bioengineered coronary graft at the EACTS Annual Meeting in Barcelona.
The Minnesota biotech presented two-year clinical patency data for its acellular bioengineered coronary graft at the EACTS Annual Meeting in Barcelona.
The Biotech Times Editorial Team  · 
Medical Devices
Regulatory Science

Manchester-led team maps path for virtual patients in device regulation

A University of Manchester-led consortium has published a framework for using computer-simulated patients to support medical device regulatory decisions.
A University of Manchester-led consortium has published a framework for using computer-simulated patients to support medical device regulatory decisions.
The Biotech Times Editorial Team  · 
Medical Devices
Digital Health
Biotech

Al Ghurair launches Trellis Health hospital network in Dubai

The UAE conglomerate's new healthcare group opens a 50-bed multi-speciality hospital in Umm Suqeim, with two further clinics due by end of
The UAE conglomerate's new healthcare group opens a 50-bed multi-speciality hospital in Umm Suqeim, with two further clinics due by end of
The Biotech Times Editorial Team  · 
Medical Devices

MMI raises $125m Series D to scale Symani robotic microsurgery

Medical Microinstruments secured the oversubscribed round to expand its Symani Surgical System globally, with around 50 systems installed and 3,500 procedures completed.
Medical Microinstruments secured the oversubscribed round to expand its Symani Surgical System globally, with around 50 systems installed and 3,500 procedures completed.
The Biotech Times Editorial Team  · 
Medical Devices

Spirair publishes six-month Vayu Study data for SeptAlign implant

Peer-reviewed results show a 63% reduction in nasal obstruction scores at six months, with no serious adverse events recorded across 75 patients.
Peer-reviewed results show a 63% reduction in nasal obstruction scores at six months, with no serious adverse events recorded across 75 patients.
The Biotech Times Editorial Team  · 
Medical Devices
Biologics

TISSIUM begins US enrolment in UNITE hernia fixation trial

TISSIUM has treated its first US patients with the ECLIPSIUM System in a 240-patient IDE trial comparing non-penetrating mesh fixation against resorbable tacks.
TISSIUM has treated its first US patients with the ECLIPSIUM System in a 240-patient IDE trial comparing non-penetrating mesh fixation against resorbable tacks.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics
Regulatory Science

SeaStar Medical wins seventh Breakthrough Device tag for SCD in sepsis

The FDA designation covers hyperinflammation in adult sepsis patients, a population with no currently approved immunomodulatory therapy.
The FDA designation covers hyperinflammation in adult sepsis patients, a population with no currently approved immunomodulatory therapy.
The Biotech Times Editorial Team  · 
Medical Devices
Pharmaceuticals
Regulatory Science

Kaléo wins $96m BARDA contract for 2-PAM nerve agent auto-injector

The Virginia biotech secured a Project BioShield award to advance its pralidoxime auto-injector through FDA approval and initial stockpile procurement.
The Virginia biotech secured a Project BioShield award to advance its pralidoxime auto-injector through FDA approval and initial stockpile procurement.
The Biotech Times Editorial Team  · 
Medical Devices
Pharmaceuticals

Elutia receives $8m Boston Scientific escrow; funded into 2029

Elutia has cleared its final 2026 funding milestone, receiving the full $8m holdback from its BioEnvelope sale with no indemnity claims.
Elutia has cleared its final 2026 funding milestone, receiving the full $8m holdback from its BioEnvelope sale with no indemnity claims.
The Biotech Times Editorial Team  · 
Subscribe to Innovation